3D BIOPRINTING WILL ENTER AUSTRALIAN SECURITIES EXCHANGE WITH KOLIGO THERAPEUTICS

3D Printing Industry | 3/11/2019 | Umair Iftikhar
Goobee (Posted by) Level 4
Click For Photo: https://3dprintingindustry.com/wp-content/uploads/2019/03/yes-yes-1024x576.png


Click For Photo: https://3dprintingindustry.com/wp-content/uploads/2019/03/yes-yes.png




Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an Initial Public Offering (IPO).

Koligo is hoping to raise up to AUD$7m at 20c a share from the IPO, establishing a market value of approximately AUD$22m. Koligo will use the funds raised through the IPO to expand its manufacturing capacity and drive sales into targeted hospitals, so that medical treatments can utilise Koligo technology. Furthermore, Koligo is looking to take advantage of opportunities for international growth, and to develop its patented 3D-V technology platform and product pipeline.

Matthew - Lehman - CEO - Koligo - Listing

Matthew Lehman, CEO of Koligo, explains, “Our listing on the ASX will accelerate Koligo’s growth and improve our ability to make a real difference in patients’ lives who suffer these debilitating conditions. The local market understands the value these companies provide. We are heartened by the success of other regenerative medicine and cell therapy companies on the ASX, such as Exopharm, Polynovo and Cynata.”

Koligo’s 3D-V bioprinting platform is intended to develop and improve its regenerative medicine products and engineer cell and tissue transplantation with 3D bioprinting technology. The 3D bioprinted products are planned for commercial release and will be used to treat serious health conditions and disorders such as pancreatitis, type 1 diabetes, liver failure and more. An example of Koligo’s 3D bioprinting processes includes Stylescel-L, where a 3D bioprinted spheroid is injected into patients to allow better oxygen and blood flow. Lehman adds:

KOLIGO - TRANSFORM - HUMAN - CELL - AND

“KOLIGO WILL TRANSFORM HUMAN CELL AND TISSUE TRANSPLANT WITH OUR 3D-V BIO-PRINTING. WE WILL CREATE 3D BIODEGRABLE BIO-PRINTED SPHEROIDS WHICH CONTAIN A PATIENT’S STROMAL VASCULAR FRACTION CELLS AND/ OR MICRO VASCULAR FRAGMENTS AND PANCREAS ISLETS […] THESE SPHEROID ‘SCAFFOLDS’ ALLOW IMPROVED FUNCTION OF THE CELL OR TISSUE AFTER TRANSPLANT AND SAFELY BIODEGRADE.”

Koligo is also committed to the wide...
(Excerpt) Read more at: 3D Printing Industry
Wake Up To Breaking News!
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!